Anti‐IL‐23 and Anti‐IL‐17 biologic agents for the treatment of immune‐mediated inflammatory conditions
J Frieder, D Kivelevitch, I Haugh… - Clinical …, 2018 - Wiley Online Library
Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)‐23
and IL‐17 as fundamental contributors in the immune pathways of the disease. Leveraging …
and IL‐17 as fundamental contributors in the immune pathways of the disease. Leveraging …
Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.
J Frieder, D Kivelevitch, I Haugh, I Watson… - Clinical Pharmacology …, 2017 - europepmc.org
Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23
and IL-17 as fundamental contributors in the immune pathways of the disease. Leveraging …
and IL-17 as fundamental contributors in the immune pathways of the disease. Leveraging …
Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions
J Frieder, D Kivelevitch, I Haugh… - Clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23
and IL-17 as fundamental contributors in the immune pathways of the disease. Leveraging …
and IL-17 as fundamental contributors in the immune pathways of the disease. Leveraging …
Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions
J Frieder, D Kivelevitch, I Haugh… - Clinical …, 2018 - utsouthwestern.elsevierpure.com
Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23
and IL-17 as fundamental contributors in the immune pathways of the disease. Leveraging …
and IL-17 as fundamental contributors in the immune pathways of the disease. Leveraging …